Bristol-Myers Squibb (BMY) Issues Encouraging Update on Nivolumab in NSCLC
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) announced long-term follow-up results (median follow up of 20.3 months) from the lung cancer cohort ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE